Novartis announced the start of GALIANT, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus? (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).
Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.
Researchers will report results of a follow-on study of the first non-invasive, diabetes-screening device that was able to significantly outperform the fasting plasma glucose (FPG) test and the A1C test for identifying diabetes and pre-diabetes in individuals with one or more known risk factors for the disease. Presented at the 2006 Scientific Assembly of the American Academy of Family Physicians, held here, the study showed a prototype of the device was able to identify 29% more patients than the FPG test and 17% more patients than the A1C test. Both the FPG and A1C are blood tests used to screen and evaluate patients at risk for diabetes.
Exercise can help people with large waistlines reduce their risk of developing type 2 diabetes, Finnish researchers said. Type 2 diabetes, the more common form of the illness caused by an inability to make or properly use insulin, is linked to being overweight or obese.
High-calorie, low-fiber diets can promote hormonal imbalances that lead children to overeat, one researcher warns.
For people with diabetes who also have abnormal levels of blood fats, or lipids, the combination of two types of cholesterol-lowering drugs seems to work better than either one alone, researchers report.
Researchers have revealed that drinking coffee, especially the decaffeinated kind, seems to offer protection against type 2 diabetes.
The link between coffee and diabetes risk appears to be consistent across different ages and body weights; in addition, most research has found that the more coffee an individual generally drinks, the lower his or her risk for diabetes.
A new study has found that elevated levels of a molecule called RBP4 (retinol binding protein 4) can foretell early stages in the development of insulin resistance, a major cause of type-II diabetes as well as cardiovascular disease.
Both type 1 and type 2 diabetes sharply raise the risk of pregnancy complications, research has found.
The prevalence of diagnosed diabetes in U.S. adults age 20 and older has risen from about 5.1 percent to 6.5 percent, according to researchers at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), who analyzed national survey data from two periods ? 1988 to 1994 and 1999 to 2002. However, the percentage of adults with undiagnosed diabetes did not change significantly over the years studied. About 2.8 percent of U.S. adults ? one-third of those with diabetes ? still don?t know they have it.